IVMD Chief Scientist Elected as Fellow of the Royal Society of Edinburgh.

INVERNESS, Scotland -- IVMD, Inc. (OTCBB:IVVO) today announced the election of Professor Patricia Connolly as Fellow of the Royal Society of Edinburgh, Scotland's National Academy of Science & Letters.

In addition to her post at IVMD (UK) Ltd., Professor Connolly is a Professor of Bioengineering at the University of Strathclyde in Glasgow, where her research work centers on medical diagnostic devices, specifically non-invasive medical sensors, rapid blood sensors and sensors for cell and tissue engineering. Previously she was a Technical Director for Nycomed Amersham (Lausanne) and Head of Research at Byk Gulden Italia (Altana Pharma), Milan, Italy, where she developed sensitive blood assay systems to a commercial level, and obtained an FDA approval for a new contrast media injector. Professor Connolly is the author of more than 60 published papers and peer-reviewed articles and several patents have resulted from her research work. She contributes actively to the training agenda for the medical devices field and is Director of the UK EPSRC-funded Medical Devices Doctoral Training Centre at the University of Strathclyde. In this center graduates from Engineering and the Physical Sciences can obtain engineering doctorate degrees at the Life Sciences Interface working on multidisciplinary, medical device research projects with end users such as clinicians and medical companies.

The Royal Society of Edinburgh (RSE) was founded in 1783 and has played an important role in the scientific life of Scotland in the years since its foundation. Its multidisciplinary, peer-elected fellowship of men and women of international standing provides independent, expert advise to key decision making bodies, including Government and Parliament.

There have been many distinguished Fellows of the Society. Adam Smith was a founder member in 1783 and since that time the Fellowship has included John Logie Baird, Charles Darwin, Albert Einstein, Michael Faraday, Alexander Fleming, Louis Pasteur, Robert Stevenson and Thomas Jefferson amongst many others of note. Currently, the Society's Honorary Fellows include Dame Muriel Spark, Sir James Black, Joseph Rotblat, Sir Paul Nurse, Lord (George) Robertson, Frederick Sanger, James Watson and Francis Crick.

The Society currently has over 1280 Ordinary Fellows, 24 Corresponding Fellows and 71 Honorary Fellows. Fellows are elected annually on the first Monday of March following a rigorous selection procedure.

IVMD, Inc. consists of the former Hall Effect Technologies, Ltd., which is now IVMD (UK) Ltd. and Jopejo Ltd. IVMD is in the final stage of developing its first groundbreaking medical device for the cardio-vascular market. Other medical conditions being addressed by IVMD's patented technology include the diabetes market and those conditions where imaging is essential. The company's technology is based on the Hall Effect and although it has been known since 1879 when E. H. Hall discovered it, it is only through recent developments in semi-conductor technology and computing power that scientists have been able to analyze the magnetic properties of bone and tissue, thereby enabling the Hall Effect to be considered in medical uses. IVMD has a substantial patent portfolio relating to its technology. Jopejo Ltd. is also in the late stages of developing new and technically superior monitoring devices that utilize signal processing for the late-term pregnancy market.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.